Dr Stefanoski: “Within the early years, Europe’s hashish trade was pushed by enthusiasm relatively than proof, a trigger greater than a class. PHCANN was constructed on the alternative basis: science, self-discipline, and affected person outcomes.
“Our mission in the present day is obvious, to ascertain medical hashish as a authentic a part of fashionable healthcare. Which means bringing pharmaceutical precision, medical accountability, and transparency to each stage, from cultivation to affected person entry.
“We’re not constructing perception, we’re constructing belief.”
Dr Stefanoski: “It means maturity has arrived.
“The trade’s credibility now is determined by constant supply, not on visionary storytelling. At PHCANN, we’ve moved from progress for consideration to progress for reliability.
“We give attention to compliance, information, and measurable high quality. Each choice, whether or not about enlargement, partnerships, or branding, is filtered by means of a easy lens: does it enhance affected person outcomes and reinforce belief with regulators and prescribers?
“The brand new period of hashish is just not about making noise; it’s about making requirements.”
Dr Stefanoski: “The following section for PHCANN is about depth, precision, and execution. We’re shifting from constructing capability to constructing continuity, increasing our product portfolio, strengthening market entry, and reinforcing our pharmaceutical self-discipline.
“A key milestone this yr is the launch of our new premium product line, PHCANN Exotics, in Germany and the UK.
“This line embodies our philosophy of high quality by means of precision, combining distinct genetics and constant cannabinoid profiles. In Germany, PHCANN Exotics will place us within the high-end prescription phase, whereas within the UK it can introduce a brand new degree of selection and consistency for prescribers and sufferers. Along with the Tyson 2.0 model, for which we’re unique producers for Europe, this can provide sufferers a wider portfolio of selection.
“On the similar time, we’re finalising new product registrations in Australia and Poland, aligning all launches below one harmonised EU-GMP framework.
“Internally, we’re investing in digital high quality techniques and information integration, linking cultivation, manufacturing, and stability analytics right into a unified platform. This infrastructure offers us full traceability and sooner responsiveness as we scale.”
